Benzamides have shown promise in the treatment of various types of cancer, including but not limited to:
- Breast Cancer: PARP inhibitors like niraparib have been approved for the treatment of advanced or recurrent breast cancer, particularly in patients with BRCA mutations. - Prostate Cancer: HDAC inhibitors such as vorinostat are being investigated for their potential to treat advanced prostate cancer, often in combination with other therapies. - Lung Cancer: Benzamides are also being explored for their efficacy in treating small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with several compounds currently in clinical trials.
